ABSTRACT
Over the last decade much of the pharmacologic market for overactive bladder (OAB) has evolved into a spectrum of extended release medications. The newer medications have been designed with novel delivery mechanisms to prolong their efficacy and reduce their side effects. Where does that leave the “older”, immediate release (IR) agents in the treatment of the overactive bladder?
